Related Experiment Video
Updated: Jun 26, 2025
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody
Bryony Treston1, Sarah Geoghegan1,2
1Department of Paediatric Infectious Diseases, Children's Health Ireland at Crumlin and Temple Street, Dublin, Ireland.
Insights
Two new options for infant Respiratory Syncytial Virus (RSV) protection are available: nirsevimab and RSV-PreF. Understanding parental vaccine decisions is key to successful RSV prevention strategies for infants.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Respiratory Syncytial Virus (RSV) is a major global health concern, especially for infants under one year old.
- Passive immunization strategies are crucial for protecting vulnerable infant populations from severe RSV disease.
Purpose of the Study:
- To review current passive immunization products for infant RSV: nirsevimab (long-acting monoclonal antibody) and RSV-PreF (maternal vaccine).
- To emphasize the importance of parental acceptance and uptake for the success of national RSV immunization strategies.
- To identify factors influencing parental decisions regarding infant immunization to improve healthcare communication and RSV prevention.
Main Methods:
- Literature review of existing RSV passive immunization products.
- Analysis of factors influencing parental decision-making in vaccination.
- Synthesis of information to inform healthcare communication and strategy development.
Main Results:
- Two novel passive immunization products, nirsevimab and RSV-PreF, are now available for infant RSV prevention.
- Parental acceptance and uptake are critical determinants of the effectiveness of these new interventions.
- Understanding parental concerns is essential for designing effective communication and prevention strategies.
Conclusions:
- Nirsevimab and RSV-PreF represent significant advancements in protecting infants from RSV.
- Effective national immunization strategies require a deep understanding of parental perspectives on infant vaccination.
- Future efforts should focus on informed discussions and tailored communication to enhance the uptake of these vital RSV prevention tools.
Abstract:
Respiratory Syncytial Virus poses a significant global public health threat, particularly affecting infants aged less than one year of age. Recently, two forms of passive immunization against infant RSV have been developed and brought to market; nirsevimab a long-acting monoclonal antibody (mAb) and RSV-PreF, a maternal RSV vaccine. The acceptability and uptake of these products will play a pivotal role in determining the success of any national immunization strategy aimed at safeguarding infants from RSV. It is crucial at this time to reflect on the factors that influence parental decisions surrounding immunization to facilitate more informed discussions, enhance healthcare communication, and contribute to the design of effective RSV prevention strategies that resonate with the concerns and aspirations of parents worldwide.
More Related Videos
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
13:00Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
Published on: July 31, 2021
Related Concept Videos
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:19Rh Blood Group